Faron Pharmaceuticals Oy (FARN.L)
GBp 175.0
(2.94%)
GBp 175.0
(2.94%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -28.37 Million EUR | -4.96% |
| 2022 | -27.05 Million EUR | -30.98% |
| 2021 | -20.65 Million EUR | -26.88% |
| 2020 | -16.5 Million EUR | -27.17% |
| 2019 | -12.78 Million EUR | 34.5% |
| 2018 | -19.86 Million EUR | 6.62% |
| 2017 | -20.58 Million EUR | -131.65% |
| 2016 | -9.62 Million EUR | -52.36% |
| 2015 | -5.92 Million EUR | -387.17% |
| 2014 | -1.18 Million EUR | 14.37% |
| 2013 | -1.42 Million EUR | 40.08% |
| 2012 | -2.37 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -5566.00 EUR | 0.0% |
| 2024 Q1 | -5566.00 EUR | 29.24% |
| 2023 Q3 | -7866.50 EUR | -24.49% |
| 2023 Q4 | -7866.50 EUR | 0.0% |
| 2023 FY | - EUR | -4.96% |
| 2023 Q1 | -6319.00 EUR | 9.69% |
| 2023 Q2 | -6319.00 EUR | 0.0% |
| 2022 Q3 | -6983.00 EUR | -5.71% |
| 2022 Q4 | -6996.75 EUR | -0.2% |
| 2022 FY | - EUR | -30.98% |
| 2022 Q1 | -6606.00 EUR | -24.45% |
| 2022 Q2 | -6606.00 EUR | 0.0% |
| 2021 Q2 | -5141.00 EUR | 0.0% |
| 2021 Q4 | -5308.25 EUR | -0.23% |
| 2021 Q3 | -5295.83 EUR | -3.01% |
| 2021 FY | - EUR | -26.88% |
| 2021 Q1 | -5141.00 EUR | -8.73% |
| 2020 Q2 | -3507.50 EUR | 0.0% |
| 2020 Q1 | -3507.50 EUR | -4.62% |
| 2020 Q3 | -4715.33 EUR | -34.44% |
| 2020 FY | - EUR | -27.17% |
| 2020 Q4 | -4728.25 EUR | -0.27% |
| 2019 FY | - EUR | 34.5% |
| 2019 Q1 | -3147.50 EUR | -6.84% |
| 2019 Q2 | -3147.50 EUR | 0.0% |
| 2019 Q3 | -3352.50 EUR | -6.51% |
| 2019 Q4 | -3352.50 EUR | 0.0% |
| 2018 FY | - EUR | 6.62% |
| 2018 Q4 | -2946.00 EUR | 0.0% |
| 2018 Q3 | -2946.00 EUR | 57.91% |
| 2018 Q2 | -6998.50 EUR | 0.0% |
| 2018 Q1 | -6998.50 EUR | -1.56% |
| 2017 Q1 | -3400.50 EUR | -8.26% |
| 2017 Q2 | -3400.50 EUR | 0.0% |
| 2017 FY | - EUR | -131.65% |
| 2017 Q4 | -6891.00 EUR | 0.0% |
| 2017 Q3 | -6891.00 EUR | -102.65% |
| 2016 Q2 | -1651.50 EUR | 0.0% |
| 2016 Q4 | -3141.00 EUR | -0.21% |
| 2016 FY | - EUR | -52.36% |
| 2016 Q3 | -3134.33 EUR | -89.79% |
| 2016 Q1 | -1651.50 EUR | 5.22% |
| 2015 FY | - EUR | -387.17% |
| 2015 Q3 | -1742.50 EUR | -53.05% |
| 2015 Q4 | -1742.50 EUR | 0.0% |
| 2015 Q1 | -1138.50 EUR | -283.33% |
| 2015 Q2 | -1138.50 EUR | 0.0% |
| 2014 Q3 | -290.00 EUR | -9.02% |
| 2014 Q1 | -266.00 EUR | 0.0% |
| 2014 FY | - EUR | 14.37% |
| 2014 Q4 | -297.00 EUR | -2.41% |
| 2014 Q2 | -266.00 EUR | 0.0% |
| 2013 FY | - EUR | 40.08% |
| 2012 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|